Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Susceptibility to Behcet's disease associated with genes involved in body's immune response

Researchers with the National Institutes of Health have found susceptibility to Behcet's disease, a painful, inflammatory condition, to be associated with genes involved in the body's immune response.

14 Jul 2010

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

5 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Zeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract.

28 Jun 2010

CXCL12/CXCR4 chemokine axis plays a critical role in pathogenesis of ulcerative colitis

Ulcerative colitis (UC) is characterized by frequent diarrheal attacks and anal bleeding. Histologic characteristics of UC are the invasion of the crypt epithelium and lamina propria by peripheral blood mononuclear cells (PBMCs), disruption of the epithelial lining, and consequently mucosal ulceration and crypt abscess formation in the bowel wall.

25 Jun 2010

Cognitive-behavioral, skills-based treatment intervention program shows promise for teenagers with IBD

Disease is a private matter to many of us. For many reasons, we want to keep it to ourselves, and no cluster of disorders challenges patients' need for privacy more than inflammatory bowel disease.

10 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

ACG announces release of new IBD podcast series

The American College of Gastroenterology announced the release of a new podcast series, "Audio Q&A on Inflammatory Bowel Disease," featuring ACG experts answering questions on topics of most concern to IBD patients, their caregivers and loved ones. In recognition of World Digestive Health Day—2010 the Year of IBD, the College's new podcasts emphasize helping patients live well despite their IBD, and address issues surrounding reproduction and fertility; diet and nutrition; new and emerging therapies; the importance of clinical trials; and pediatric IBD.

28 May 2010

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Angiogenesis plays a crucial role in neoplastic and non-neoplastic chronic inflammatory disorders, including inflammatory bowel diseases (IBD). Several reports have shown that blockade of angiogenesis in preclinical models of IBD is a promising new therapeutic approach. Visualize angiogenesis in vivo may represent the first step for such a therapeutic approach. Narrow-band imaging (NBI) is a new endoscopic technology that highlights mucosal surface structures and microcapillaries.

21 May 2010

Prometheus announces novel method for early detection of HACA during infliximab treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

14 May 2010

$Inflammatory bowel disorders can raise risk of osteoporotic fractures$

Inflammatory bowel disorders can raise risk of osteoporotic fractures

A team of scientists from the University Hospitals of Geneva and Lausanne have shown that young people with inflammatory bowel diseases have low bone mass and poor bone architecture compared to healthy people of the same age, placing them at increased risk of fracture.

7 May 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

PurGenesis Technologies Inc. announced today positive results from a Phase I clinical trial on PUR0110, the Company's lead investigational new drug for the treatment of ulcerative colitis. This successful trial was designed to evaluate the safety and maximum tolerated dose of PUR0110.

6 May 2010

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.

5 May 2010

Eating more olive oil could help prevent ulcerative colitis: UEA study

Eating more olive oil could help prevent ulcerative colitis, according to a new study co-ordinated by medical researchers at the University of East Anglia.

3 May 2010

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals, Ltd. today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

29 Apr 2010

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010

Potential new treatment for osteonecrosis

28 Apr 2010

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Millions of people are afflicted with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and 30 percent of new cases occur in childhood. Mucin 1, an epithelial mucin that has been shown to elicit both an immune response and to have altered glycosylation in disease, may be a noninvasive indicator of the progression of these illnesses.

20 Apr 2010

Researchers evaluate probiotics' curative effects for treating ulcerative colitis

Inflammatory bowel disease is a chronic recurrent disease, which mainly consists of ulcerative colitis and Crohn's disease, and whose causes are as yet unclear. Many clinical and research studies have indicated that intestinal flora dysbacteriosis contributes to the pathogenesis of ulcerative colitis. Probiotics are non-pathogenic beneficial flora, which have important effects on maintaining the balance of intestinal flora.

20 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Susceptibility to Behcet's disease associated with genes involved in body's immune response

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

Plant extract effective against ulcerative colitis in mice

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

CXCL12/CXCR4 chemokine axis plays a critical role in pathogenesis of ulcerative colitis

Cognitive-behavioral, skills-based treatment intervention program shows promise for teenagers with IBD

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

ACG announces release of new IBD podcast series

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Prometheus announces novel method for early detection of HACA during infliximab treatment

Inflammatory bowel disorders can raise risk of osteoporotic fractures

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Eating more olive oil could help prevent ulcerative colitis: UEA study

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Potential new treatment for osteonecrosis

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Researchers evaluate probiotics' curative effects for treating ulcerative colitis

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in